A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment-Reference-Cited by-同舟云学术

A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment

Published:2007-03-15 Issue:6 Volume:109 Page:1114-1124
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Burnett Alan K.,Milligan Donald,Prentice Archie G.,Goldstone Anthony H.,McMullin Mary F.,Hills Robert K.,Wheatley Keith,

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference24 articles.

1. The Outcomes and Costs of Acute Myeloid Leukemia Among the Elderly

2. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group.

3. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly.

4. Response of Preleukemic Syndromes to Continuous Infusion of Low-Dose Cytarabine

5. Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia

Cited by 543 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go?;American Journal of Hematology;2024-07-17

2. All-trans retinoic acid in hematologic disorders: not just acute promyelocytic leukemia;Frontiers in Pharmacology;2024-07-04

3. Metronomic chemotherapy in hematology: Lessons from preclinical and clinical studies to build a solid rationale for future schedules;Cancer Letters;2024-06

4. Evaluating the Economic Burden of Acute Myeloid Leukemia in Canada;Acta Haematologica;2024-02-21

5. Glasdegib with intensive/nonintensive chemotherapy in Japanese patients with untreated acute myeloid leukemia or high‐risk myelodysplastic syndromes;Cancer Science;2024-02-07